TABLE 1.

Baseline characteristics of 430 patients with lymphoma receiving 1993 doses of high-dose methotrexate between 2009 and 2019 at Mayo Clinic

Characteristic	Levetiracetam N = 379 administrations	No levetiracetam N = 1614 administrations	p-Value
Male, no. (%)	162 (42.7%)	896 (55.5%)	0.13
Age, years, median (IQR)	66 (53, 72)	68 (60, 75)	0.030
Race, no. (%)
Caucasian	338 (94.9)	1533 (95.3)	0.12
Non-Caucasian	18 (5.1)	75 (4.7)
Lymphoma diagnosis, no. (%)
Systemic DLBCL	201 (53.0)	964 (59.7)	0.49
Systemic DLBCL with CNS involvement	141 (37.2)	513 (31.8)
Other	37 (9.8)	137 (8.5)
Serum creatinine, mg/dl, median (IQR)	0.8 (0.7, 0.9)	0.9 (0.7, 1.1)	0.018
Estimated creatinine clearance, no. (%)
>60 ml/min	337 (89.2)	1310 (82.0)	0.25
30–60 ml/min	41 (10.8)	287 (18.0)
<30 ml/min	0 (0.0)	0 (0.0)
Aspartate aminotransferase, units/L, median (IQR)	22 (18, 28)	21 (17, 27)	0.047
Alanine aminotransferase, units/L, median (IQR)	33 (22, 59)	30 (18, 52)	0.13
Total bilirubin, mg/dl, median (IQR)	0.4 (0.3, 0.5)	0.4 (0.3, 0.5)	0.34

Abbreviations: CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; IQR, interquartile range.